Skip to main content
. 2008 Mar 3;153(Suppl 1):S112–S119. doi: 10.1038/sj.bjp.0707654

Table 3. Phase III programme STAIR II criteria.

• Dose selection based on phase 1 and II data plasma concentrations
• Time window for drug initiation
• Patient selection based on mechanisms of action
• Outcome measures
• Severity of stroke population to be studied
• Length of follow-up period
• Use of surrogate markers to provide support for drug efficacy
• Prespecification of covariate analysis
• Fostering of appropriate and effective relationships between sponsors, academics and investigators